Drug-eluting balloon: Very short-term exposure and overlapping

Thrombosis and Haemostasis

Volumn 101, Issue 1, 2009, Pages 201-206

  Cramers, Bodo ^a   Speck, Ulrich ^b   Kaufels, Nicola ^b   Mahnkopf, Dirk ^c   Kühler, Michael ^d   Böhm, Michael ^a   Scheller, Bruno ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c IMTM GmbH   (Germany)

^d B Braun Melsungen AG   (Germany)

Author keywords

Drug eluting balloon; Inflation time; Overlap; Paclitaxel; Restenosis

Indexed keywords

PACLITAXEL; STAINLESS STEEL; BIOMATERIAL; CARDIOVASCULAR AGENT; METAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALLOON CATHETER; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OBSTRUCTION; DRUG ELUTING STENT; EXPERIMENTAL PIG; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MORPHOMETRICS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; ANGIOCARDIOGRAPHY; ANIMAL; CORONARY BLOOD VESSEL; DRUG EFFECT; EQUIPMENT DESIGN; EVALUATION; INSTRUMENTATION; MATERIALS TESTING; PATHOLOGY; RADIOGRAPHY; STENT; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOVASCULAR AGENTS; CELL PROLIFERATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY VESSELS; EQUIPMENT DESIGN; MATERIALS TESTING; METALS; MODELS, ANIMAL; PACLITAXEL; STENTS; SUS SCROFA;

EID: 60849087970     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-06-0387     Document Type: Article

References (21)

1. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001; 103:2289-2295,
2. Morice MC, Serruys PW. Sousa JE, et al, A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization, N Engl J Med 2002; 346: 1773-1780.
3. Fattori R, Tommaso P. Drug-eluting stents in vascular intervention. Lancet 2003; 361: 247-249.
4. Stone GW, Ellis SG, Cox DA, et al, A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
5. Iofina E, Langenberg R, Blindt R, et al. Polymerbased paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. Am J Cardiol 2006; 98: 1022-1027.
6. Maisel WH. Unanswered questions. Drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007; 356: 981-984,
7. Mori T, Kinoshita Y, Watanabe A, et al. Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol 2006; 58: 665-672.
8. Scheller B, Speck U, Romeike B, et al. Contrast media as carriers for local drug delivery. Successful in- hibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003; 24: 1462-1467.
9. Scheller B, Speck U, Schmitt A, et al. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol 2003; 42: 1415-1420.
10. Scheller B. Speck U, Abramjuk C, et al, Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-814.
11. Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: comparison of effectiveness of non-stentbased local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology 2006; 240: 411-418.
12. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated ballooncatheter. N Engl J Med 2006; 355: 2113-2124.
13. Schwartz RS, Huber KC, Murphy JG, et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model, J Am Coll Cardiol 1992; 19: 267-274.
14. Kornowski R, Hong MK, Tio FO, et al, In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998; 31: 224-230.
15. Axel DT, Kunert W, Goggelmann C, et al, Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997; 96: 636-645.
16. Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stentbaseddehvery. Circulation 2001; 104: 600-605.
17. Lansky AJ, Costa RA, Mintz GS, et al. Nonpolymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109: 1948-1954.
18. Schwartz RS, Edelman ER, Carter A, et al. Preclinical evaluation of drug-eluting stents for peripheral applictions: recommendations from an expert consensus group. Circulation 2004; 110:2498-2505.
19. Carter AJ, Aggarwal M, Kopia GA, et al. Longterm effects of polymer-based, slowrelease, sirolimus-eluting stents in a porcine coronary model, Cardiovasc Res 2004; 63: 617-624.
20. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymercoated stent. Circulation 2001; 104: 473-479.
21. Dommke C, Haase KK, Süselbeck T, et al. Local paclitaxel delivery after coronary stenting in an experimental animal model. Thromb Haemost 2007; 98: 674-680.